[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580772":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":22,"responsibleParty":40,"collaborators":42,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Regina Elena Cancer Institute","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Retrospective cohort",null,"Fresh tissue samples stored at -80°C, collected at the Institute's IRE Biobank (a starting from 2019) and tissue preserved in paraffin at the biobank at 4°C at the UOC Pathological Anatomy archive, for carrying out WES, RNA-seq, scRNA-seq, spatial transcriptomics, metabolomics, proteomics, digital pathology, immune infiltrate characterization (e.g. FACS, immunohistochemistry)",{"label":13,"type":10,"description":14,"interventionNames":10},"Prospective cohort","Collection of tissue samples obtained at the time of surgery and verified by the anatomical pathologist for the actual availability and adequacy, for the purpose of the creation of organoids (Patient-Derived Organoids, PDO), cell lines and co-cultures (created with the patient's own peripheral immune cells, collected and processed), in the context of which secretomics analyzes will be conducted using Olink and Luminex.",[16],{"name":17,"role":18,"phone":19,"phoneExt":20,"email":21},"Enrico Vizza, Doctor","CONTACT","06 52666974","+39","enrico.vizza@ifo.it",[23],{"facility":24,"status":25,"city":26,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"IRCCS National Cancer Institute \"Regina Elena\"","RECRUITING","Rome","00144","Italy","IT",{"type":31,"coordinates":32},"Point",[33,34],12.51133,41.89193,{"lat":34,"lon":33},[37],{"name":38,"role":18,"phone":39,"phoneExt":20,"email":21},"Enrico Vizza, Medical Doctor","+39 06-52666974",{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[43,45,48],{"name":44,"class":6},"University of Rome Tor Vergata",{"name":46,"class":47},"Casa Sollievo della Sofferenza-IRCCS, San Giovanni Rotondo","UNKNOWN",{"name":49,"class":6},"Universita degli Studi di Palermo","100580772","ai-and-machine-learning-based-risk-prediction-model-to-improve-the-clinical-management-of-endometrial-cancer-100580772",false,"NCT06841653","A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer.","A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer: a Composite Approach Integrating the MultiOMics IMmune-IConographic Pattern (MOMIMIC Score) Towards Precision Oncology and Surgery.","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Histological diagnosis of endometrial hyperplasia, endometrioid adenocarcinoma of the endometrium, healthy endometrium in patients undergoing total hysterectomy for benign extra-endometrial disease;\n* Written informed consent (to the study and data processing), for the party's patients only prospective and\u002For in follow-up) For the retrospective cohort: availability of samples adequately stored at the biobank of the Institute and availability of data relating to follow-up (at least 2 years)\n\nExclusion Criteria:\n\nAll exclusion criteria adopted in the surgical protocols will be applied to the study. In particular:\n\n* Comorbidities not controlled with adequate medical therapy;\n* Infections of the endometrial cavity (pyometra);\n* Synchronous cancer;\n* Neoadjuvant treatments;\n* Previous radiotherapy treatments of the pelvic region;\n* Hormone therapies.","FEMALE","18 Years",{"count":60,"type":61},40,"ESTIMATED","OBSERVATIONAL","Prediction of preoperative endometrial biopsy: the evolution from hyperplasia to cancer, the prognosis and the risk of recurrence. Intelligence methods artificial risk will be used to redefine the current risk classes including our profile immuno-mutational to provide a more precise characterization and closer to the real prognosis of the patient.",[65],"Endometrium Cancer",[67],"MultiOMics IMmune-IConographic pattern","2025-02-18",{"date":70,"type":71},"2025-02-24","ACTUAL",{"date":73,"type":71},"2024-06-20",{"date":75,"type":61},"2026-06-20",{"name":5,"class":6},1]